. Overview We are a clinical-stage biopharmaceutical company dedicated to the development of novel therapeutics for high unmet medical needs, including treatment-resistant metastatic breast cancer and amyotrophic lateral sclerosis (ALS), with the goal of improving patients lives. Following a review of potential therapeutic and business opportunities, we acquired rights to a promising late-stage asset, lasofoxifene, for the potential treatment of ESR1-mutated (mESR1) metastatic breast cancer in D...
Q2 FY2026 — expected 2026-09-13
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2026-03-31 | 2025-12-31 | 0001193125-26-134565 | EDGAR | 117K words |
| 2025-02-27 | 2024-12-31 | 0000950170-25-029069 | EDGAR | — |
| 2024-02-22 | 2023-12-31 | 0000950170-24-018787 | EDGAR | — |
| 2023-03-23 | 2022-12-31 | 0000950170-23-009498 | EDGAR | — |
| 2022-03-28 | 2021-12-31 | 0000950170-22-004782 | EDGAR | — |
| 2021-03-25 | 2020-12-31 | 0001564590-21-015495 | EDGAR | — |
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2025-11-06 | 2025-09-30 | 0001193125-25-269544 | EDGAR | 67K words |
| 2025-08-07 | 2025-06-30 | 0000950170-25-105052 | EDGAR | — |
| 2025-05-09 | 2025-03-31 | 0000950170-25-068040 | EDGAR | — |
| 2024-11-07 | 2024-09-30 | 0000950170-24-123372 | EDGAR | — |
| 2024-08-01 | 2024-06-30 | 0000950170-24-089304 | EDGAR | — |
| 2024-05-15 | 2024-03-31 | 0000950170-24-060482 | EDGAR | — |
| 2023-11-09 | 2023-09-30 | 0000950170-23-062082 | EDGAR | — |
| 2023-08-10 | 2023-06-30 | 0000950170-23-041346 | EDGAR | — |
| 2023-05-11 | 2023-03-31 | 0000950170-23-021274 | EDGAR | — |
| 2022-11-10 | 2022-09-30 | 0000950170-22-024499 | EDGAR | — |
| 2022-08-15 | 2022-06-30 | 0000950170-22-017421 | EDGAR | — |
| 2022-05-12 | 2022-03-31 | 0000950170-22-009683 | EDGAR | — |
| Filed | Accession | Source | Full Text |
|---|---|---|---|
| 2026-03-26 | 0001193125-26-126579 | EDGAR | 3K words |
| 2026-03-19 | 0001193125-26-116123 | EDGAR | — |
| 2026-01-09 | 0001193125-26-008904 | EDGAR | — |
| 2025-12-18 | 0001193125-25-323692 | EDGAR | — |
| 2025-11-06 | 0001193125-25-269506 | EDGAR | — |
| 2025-10-03 | 0001193125-25-229293 | EDGAR | — |
| 2025-09-11 | 0000950170-25-114093 | EDGAR | — |
| 2025-08-07 | 0000950170-25-105029 | EDGAR | — |
| 2025-06-02 | 0000950170-25-080234 | EDGAR | — |
| 2025-05-09 | 0000950170-25-068020 | EDGAR | — |
93 total filings indexed. 65 additional filings (S-1, DEF 14A, etc.) View all (JSON) · SEC EDGAR
| CIK | 0001620463 |
| Ticker | LONA |
| Exchange | Nasdaq |
| SIC | 2836: Biological Products, (No Diagnostic Substances) |
| Website | https://www.leonabio.com |
| Listed | 2020-09-18 |
This is the free public profile. For structured JSON with full provenance chain, use the API:
JSON Profile Stock Quote AI Readiness Report